Gibson Wealth Advisors’s GSK GSK Stock Holding History

Gibson Wealth Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$8K	Buy	252 +248	+6,200%	+$8.26K	﹤0.01%	117
2022 Q3	$0	Buy	+4	New	+$152	﹤0.01%	121
2022 Q2	–	Sell	-5	Closed	–	–	121
2022 Q1	$0	Hold	5	–	–	﹤0.01%	125
2021 Q4	$0	Buy	+5	New	+$260	﹤0.01%	108

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Gibson Wealth Advisors's GSK Position: Q4 2022 in Review

Gibson Wealth Advisors increased its GSK (GSK) stake by 6,200% in Q4 2022, buying an estimated $8.26K and bringing the position to 252 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #117.

Gibson Wealth Advisors first reported a position in GSK in Q4 2021 and has held it in 4 quarters since. 813 funds tracked by Wall St. Rank hold GSK as of Q4 2022.

Gibson Wealth Advisors held 252 shares of GSK worth $8K as of Q4 2022.
Gibson Wealth Advisors bought 248 GSK shares in Q4 2022, an estimated $8.26K.
GSK made up ﹤0.01% of Gibson Wealth Advisors's portfolio in Q4 2022, its #117 holding.
Gibson Wealth Advisors first reported a position in GSK in Q4 2021 and has held it in 4 quarters since.
813 funds tracked by Wall St. Rank held GSK as of Q4 2022.

Based on Gibson Wealth Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.